PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis; VEXAS syndrome
- Focus Therapeutic Use
- Sponsors Swedish Orphan Biovitrum
- 22 Jan 2025 New trial record